Terence Flynn
Stock Analyst at Morgan Stanley
(4.31)
# 401
Out of 5,090 analysts
220
Total ratings
60.18%
Success rate
13.02%
Average return
Main Sectors:
Stocks Rated by Terence Flynn
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| VRTX Vertex Pharmaceuticals | Upgrades: Overweight | $438 → $516 | $458.10 | +12.64% | 2 | Dec 3, 2025 | |
| MRK Merck & Co. | Maintains: Buy | $92 → $120 | $100.56 | +19.33% | 19 | Dec 2, 2025 | |
| LLY Eli Lilly and Company | Maintains: Overweight | $1,171 → $1,290 | $1,013.00 | +27.34% | 23 | Nov 24, 2025 | |
| BHVN Biohaven | Maintains: Overweight | $54 → $26 | $9.37 | +177.48% | 4 | Nov 18, 2025 | |
| OGN Organon & Co. | Maintains: Equal-Weight | $10 → $9 | $7.15 | +25.87% | 11 | Nov 11, 2025 | |
| AMGN Amgen | Maintains: Equal-Weight | $333 → $329 | $333.17 | -1.25% | 10 | Nov 5, 2025 | |
| JNJ Johnson & Johnson | Maintains: Equal-Weight | $178 → $190 | $201.22 | -5.58% | 25 | Oct 15, 2025 | |
| NRIX Nurix Therapeutics | Maintains: Equal-Weight | $16 → $15 | $17.59 | -14.72% | 6 | Oct 14, 2025 | |
| PFE Pfizer | Maintains: Equal-Weight | $33 → $32 | $25.70 | +24.51% | 19 | Oct 10, 2025 | |
| RPRX Royalty Pharma | Maintains: Overweight | $55 → $54 | $38.99 | +38.51% | 13 | Oct 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $133 → $131 | $95.85 | +36.67% | 5 | Oct 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $328 → $435 | $483.05 | -9.95% | 11 | Oct 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $23 → $22 | $10.20 | +115.69% | 2 | Aug 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $22 → $23 | $24.82 | -7.33% | 8 | Aug 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $250 → $255 | $225.28 | +13.19% | 18 | Aug 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $36 → $34 | $52.15 | -34.80% | 11 | Jul 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $12 → $11 | $12.72 | -13.52% | 9 | May 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $30 → $32 | $58.15 | -44.97% | 7 | Feb 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Equal-Weight | $56 → $11 | $9.53 | +15.42% | 5 | Jan 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $118 | $33.07 | +256.82% | 1 | Sep 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $1 → $8 | $2.59 | +209.48% | 5 | Feb 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $246 → $436 | $181.65 | +140.02% | 3 | Jun 14, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | n/a | $462.51 | - | 2 | Oct 2, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $8.37 | - | 1 | Jul 21, 2017 |
Vertex Pharmaceuticals
Dec 3, 2025
Upgrades: Overweight
Price Target: $438 → $516
Current: $458.10
Upside: +12.64%
Merck & Co.
Dec 2, 2025
Maintains: Buy
Price Target: $92 → $120
Current: $100.56
Upside: +19.33%
Eli Lilly and Company
Nov 24, 2025
Maintains: Overweight
Price Target: $1,171 → $1,290
Current: $1,013.00
Upside: +27.34%
Biohaven
Nov 18, 2025
Maintains: Overweight
Price Target: $54 → $26
Current: $9.37
Upside: +177.48%
Organon & Co.
Nov 11, 2025
Maintains: Equal-Weight
Price Target: $10 → $9
Current: $7.15
Upside: +25.87%
Amgen
Nov 5, 2025
Maintains: Equal-Weight
Price Target: $333 → $329
Current: $333.17
Upside: -1.25%
Johnson & Johnson
Oct 15, 2025
Maintains: Equal-Weight
Price Target: $178 → $190
Current: $201.22
Upside: -5.58%
Nurix Therapeutics
Oct 14, 2025
Maintains: Equal-Weight
Price Target: $16 → $15
Current: $17.59
Upside: -14.72%
Pfizer
Oct 10, 2025
Maintains: Equal-Weight
Price Target: $33 → $32
Current: $25.70
Upside: +24.51%
Royalty Pharma
Oct 10, 2025
Maintains: Overweight
Price Target: $55 → $54
Current: $38.99
Upside: +38.51%
Oct 10, 2025
Maintains: Overweight
Price Target: $133 → $131
Current: $95.85
Upside: +36.67%
Oct 10, 2025
Maintains: Equal-Weight
Price Target: $328 → $435
Current: $483.05
Upside: -9.95%
Aug 15, 2025
Maintains: Overweight
Price Target: $23 → $22
Current: $10.20
Upside: +115.69%
Aug 7, 2025
Maintains: Overweight
Price Target: $22 → $23
Current: $24.82
Upside: -7.33%
Aug 1, 2025
Maintains: Overweight
Price Target: $250 → $255
Current: $225.28
Upside: +13.19%
Jul 10, 2025
Maintains: Underweight
Price Target: $36 → $34
Current: $52.15
Upside: -34.80%
May 9, 2025
Maintains: Equal-Weight
Price Target: $12 → $11
Current: $12.72
Upside: -13.52%
Feb 14, 2025
Maintains: Underweight
Price Target: $30 → $32
Current: $58.15
Upside: -44.97%
Jan 27, 2025
Downgrades: Equal-Weight
Price Target: $56 → $11
Current: $9.53
Upside: +15.42%
Sep 23, 2024
Initiates: Overweight
Price Target: $118
Current: $33.07
Upside: +256.82%
Feb 26, 2024
Maintains: Equal-Weight
Price Target: $1 → $8
Current: $2.59
Upside: +209.48%
Jun 14, 2021
Maintains: Neutral
Price Target: $246 → $436
Current: $181.65
Upside: +140.02%
Oct 2, 2017
Upgrades: Buy
Price Target: n/a
Current: $462.51
Upside: -
Jul 21, 2017
Downgrades: Neutral
Price Target: n/a
Current: $8.37
Upside: -